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A B S T R A C T
Background
Despite the advent and increasingly wide availability of antiretroviral therapy, cryptococcal meningitis (CM) remains a significant cause
of mortality and morbidity amongst individuals with HIV infection in resource-limited settings. The ideal management of CM remains
unclear. The aim of this review is to assess the evidence for deciding on which antifungal regimen to use as well as other modalities
of management to utilise especially resource poor settings in order to achieve the best possible outcome and enable an individual with
CM to survive their acute illness and benefit from antiretroviral therapy.
Objectives
To determine the most effective initial and consolidation treatment strategy for CM in HIV infected adults.
Search methods
The Cochrane HIV/AIDS group search strategy was used. Key words in the search included, meningitis, cryptococcus neoformans,
treatment, trial, human immunodeficiency virus, acquired immunodeficiency syndrome, antifungal agents, amphotericin, flucytosine,
fluconazole, azole, lumbar puncture, cerebrospinal fluid (CSF) pressure and acetazolamide.
Selection criteria
Randomised of HIV-infected adults with a first episode of CM diagnosed on CSF examination, by India ink staining, CSF culture or
cryptococcal antigen testing.
Data collection and analysis
Data were extracted using standardised forms and analysed using Rev Man 4.2.7 software.
Main results
Six studies are included in the review. Five of the studies compared antifungal treatments and one study addressed lowering intracranial
pressure. This study was stopped early due to excess adverse effects. The results of the other five studies as summarised as follows.
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Mayanja-Kizza 1998 compared fluconazole to fluconazole with 5 flucytosine. The dose of fluconazole used 200mg initially is lower
than the recommended initial dose of 400mg. No survival advantage was found with the use of 5 flucytosine in addition to fluconazole.
Two studies Brouwer 2004 and van der Horst 1997 compared Amphotericin (AmB) to AmB with 5 flucytosine. Both drugs were given
at currently recommended doses for 2 weeks. No survival difference was found at 14 days or at 10 weeks (only recorded in Brouwer
2004). There were significantly more patients with sterile CSF cultures at 14 days in the group that received AmB with flucytosine.
Brouwer 2004 compared AmB given alone to AmB given with flucytosine and fluconazole alone or in combination. This was a small
study and no differences in mortality were noted between the groups.
Bicanic 2008 compared high to standard dose AmB both with flucytosine. There was no difference in mortality between the two groups
or adverse events.
Leenders 1997 compared standard AmB to liposomal AmB. There was no difference in death rates between the two groups. But there
were significantly fewer side effects in the group treated with liposomal AmB.
Authors’ conclusions
The main aim of this review was to determine the best treatment for cryptococcal meningitis in resource-limited settings. In these
settings usually only AmB and fluconazole are available. No studies suitable for inclusion in the review were found that compared these
two drugs. Therefore we are unable to recommend either treatment as superior to the other. The recommended treatment for CM is
a combination of AmB and flucytosine. The optimal dosing of AmB remains unclear. Liposomal AmB is associated with less adverse
events than AmB and may be useful in selected patients where resources allow.
Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most effective use of
medications that are available in these settings.
Flucytosine in combination with AmB leads to faster and increased sterilisation of CSF compared to using AmB alone. As Flucytosine
is often not available in developing countries, policy makers and national departments of heath should consider procuring this drug
for HIV treatment programmes.
P L A I N L A N G U A G E S U M M A R Y
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings
Despite the advent and increasingly wide availability of antiretroviral therapy for people with HIV/AIDS, cryptococcal meningitis
remains a significant cause of death and illness amongst individuals with HIV infection in resource-limited settings (poor countries).
The ideal way to manage cryptococcal meningitis remains unclear. The main aim of this review was to determine the best treatment
for cryptococcal meningitis in resource-limited settings. In these settings, usually only Amphotericin and fluconazole are available. The
authors didn’t find any suitable studies that compared these two drugs. Because Flucytosine, which works well with Amphotericin,
is often not available in poor countries, policy makers and government officials should consider using this drug for HIV treatment
programmes. Future research into the management of cryptococcal meningitis in resource-limited settings should focus on the most
effective use of medications that are available in these settings.
B A C K G R O U N D
Cryptococcal meningitis (CM) was first described in 1905. It is
an infection of the brain parenchyma and sub-arachnoid space by
the encapsulated saprophytic yeast organism Cryptococcus neofor-
mans, of which there are three subtypes - var gatti, var neoformans
and var grubbi(Lee 1996). Before the global human immunod-
eficiency virus (HIV) pandemic the main pathogenic strain was
C. neoformans var gatti, which is a rare cause of meningitis in im-
munocompetent individuals in several tropical countries.
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Over the last twenty years,HIV has created a large and severely im-
munocompromised population to whom C.neoformans is a dan-
gerous opportunistic infection. The major burden of disease is in
South-East Asia and the African sub-continent. During the 1990’s
CM was the leading reported cause of adult meningitis in parts of
Africa (Maher 1994, Moosa 1997, Mwaba 2001), and 10-30% of
AIDS deaths are attributed to the disease (French 2002, Bicanic
2005, Day 2004). This makes it the second leading cause of death
in HIV-infected individuals in Africa after tuberculosis. The ma-
jority of these patients are infected with sub-type C. neoformans
var grubbi (Casadevall 2001) and infection predominantly occurs
in patients with a CD4 counts of less than 100x106 cells/l (French
2002, Saag 2000). CM is classified as a World Health Organisa-
tion HIV / AIDS stage 4 disease.
Over 75%of patients withCMpresent with headache(Day 2004),
usually evolving over 2-4 weeks. Fever, nausea, vomiting and
seizures are common, but neck stiffness and classical signs of
meningism are seen in less than 25% of cases; confusion or be-
haviour change may be the only sign of infection (French 2002,
Day 2004). Sub-acute dementia can develop, which is reversible
with treatment. Space occupying lesions such as cryptococcomas,
sub-dural effusions and spinal cord granulomas are occasionally
seen and present with focal neurological signs. Visual impairment
can occur and blindness is a long-term complication of infection in
some immunocompetent patients(Seaton 1997 (a), Seaton 1997
(b)). CM reduces the absorption of cerebrospinal fluid (CSF) lead-
ing to raised intracranial pressure (ICP). High ICP is responsible
for many of the signs, symptoms and sequelae of CM.
Transmission of C. neoformans is usually by inhalation. A symp-
tomatic respiratory illness may occur but this is rare in HIV-in-
fected patients(Casadevall 2001). The skin is commonly involved
as amanifestation of disseminated disease. Cutaneous lesions often
resemble molluscum contagiosum but a wide spectrum of plaques
and papules have been reported, especially in the immunocom-
promised population.
DiagnosingCMrequires the examination ofCSF. Indian Ink stain-
ing is the cheapest technique and is relatively easy to perform in
developing countries. It has 75% sensitivity on a centrifuged sam-
ple(Day 2004). A more reliable but expensive test is Cryptococcal
antigen detection, which has 99% sensitivity in subjects with titres
> 1:2048 (Van der Horst 1997). Fungal culture has a sensitivity
of 90%. Microscopic and biochemical features of positive CSF
analysis may include amoderate mononuclear leucocytosis, mildly
elevated protein and slightly low CSF/blood glucose ratio. These
parameters may be normal in 17% of HIV patients with known
cryptococcal disease (Moosa 1997). Computer tomography brain
imaging is of limited supportive diagnostic value as the scan is
normal in 50% of proven cases. It can be justified in some cases,
however, to exclude mass lesions and other HIV-related pathology
(e.g. toxoplasmosis, CNS lymphoma).
HIV associated CM carries a high mortality even when treated
appropriately, a study from Thailand reported 43% mortality in
patients treated in a tertiary facility, with themajority of the deaths
occurring in the first two weeks of therapy (Imwidthaya 2000).
Three main groups of anti-fungal drugs are used in treatment,
amphotericin B (AmB), flucytosine and the azoles. Drug toxicity
has been found to be a problem and is reported in up to 60% of
patients (Day 2004).
AmB, the traditional mainstay of therapy, can be given intra-
venously, or, rarely, intrathecally, but it has poor oral bioavailabil-
ity. Although actively fungicidal, it is associated with significant
nephrotoxicity. This can be reduced by giving intravenous normal
saline pre-medication. Liposomal amphotericin preparations are
associated with fewer side effects but are very expensive not avail-
able in resource poor settings.
Intra-venous or oral flucytosine displays synergy with AmB. It
cannot be used asmonotherapy because of rapidly developing drug
resistance and significant gastro-intestinal side effects may develop
(Saag 2000,Graybill 1997).Drug levels or haematologicalmarkers
need to be monitored.
The azole compounds (e.g. fluconazole, itraconazole, ketocona-
zole) were introduced in the 1980s as effective, well tolerated oral
and intravenous anti-fungals. Their action against cryptococcal
disease has been well described.
Most modern treatment protocols for CM involve combinations
of the above drugs. The Infectious Diseases Society of America
recommends a 3 step treatment approach - induction (2 weeks of
AmB 0.7-1mg/kg/day plus flucytosine 100mg/kg/day) followed
by consolidation (8 weeks of fluconazole 400mg/day) and then
maintenance (fluconazole 200mg/day for life)(Saag 2000) but
some commentators have questioned the scientific evidence be-
hind this(Day 2004).Other proposed regimes include prolonged
courses of AmB and flucytosine, fluconazole and flucytosine dual
therapy and the use of AmB alone. In much of the developing
world fluconazole is the only drug available, via a donation pro-
gramme and azole based monotherapy is widely used. A number
of these regimes are based on anecdotal reports of open-label phase
II clinical trials and the rationale for their use has never been rig-
orously reviewed.
Raised ICP, is common in CM occurring in more than 50% of
patients(Graybill 1997). Raised ICP during the first 2 weeks of
treatment is associated with a poor clinical response and careful
management of ICP is thought to reduce mortality and long term
sequelae. Proposed mechanisms to reduce ICP include repeated
lumbar puncture, drain insertion and ventriculo-peritoneal shunt-
ing(Denning 1991). Mannitol, acetazolamide and corticosteroids
have also been tried, but the effects of these interventions are, at
best, unproven.
Initial antifungal treatment rarely eradicates C.neoformans in HIV
infected patients but symptomsmay improve and control of infec-
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tion is obtainable with secondary prophylaxis. With the advent of
antiretroviral therapy this picture may change with patients that
are initially treated with antifungal agents being established on an-
tiretroviral therapy and no longer needing secondary prophylaxis
as their immune system improves (Vibhagool 2003). Combina-
tion antiretroviral therapy (ART) is becoming increasingly avail-
able in the developing world, many patients in these setting still
present with a major opportunistic infection such as CM having
not known they were HIV infected. Defining effective evidence
based protocols for treatment of CM is important in these patients
if they are to benefit from subsequent ART. The timing of initiat-
ing ART after acute CM has not been well studied.
The mainstay of treatment for CM in the developing world is flu-
conazole, which in many cases is the only drug available. The aim
of this review will be to look at trials comparing the current gold
standard of treatmentAmB(oftenwith flucytosine) to fluconazole.
Liposomal and standard AmB will be compared, although liposo-
mal AmB is usually not available outside well resourced countries
and centres. Also combinations of treatment will be compared and
interventions to manage raised ICP.
This review will not look at primary or secondary prophylaxis
against cryptococcal infection.
O B J E C T I V E S
To determine the most effective initial and consolidation treat-
ment strategy for CM in HIV infected adults with an emphasis
on resource-limited countries.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled blinded and unblinded trials
Types of participants
HIV-infected adults (Aged >18) with a first episode of CM diag-
nosed on CSF examination, by India ink staining, CSF culture or
cryptococcal antigen testing.
Acute CM will be defined as a first episode of CM, for which
no treatment has been given prior to study entry and which has
been diagnosed no longer than two weeks before commencing
therapy. Studies including patients receiving antiretroviral therapy
were allowed and are commented on in the results and discussion
section.
Types of interventions
1. Antifungal agents that may be available in resource-limited and
other settings (AmB, liposomal AmB, flucytosine and fluconazole)
given alone or in combination for the initial treatment and con-
solidation treatment of acute CM.
2. Drugs and procedures used to reduce raised ICP in patients
with acute CM.
Types of outcome measures
Primary outcomes
1. Proportion of patients alive two weeks after commencing ther-
apy.
2. Proportion of patients alive at the end of the follow up period.
2. Major adverse events secondary to treatment.
Secondary outcomes
1. Proportion of patients with sterile CSF after two weeks of ther-
apy
2. Proportion of patients who have symptomatic improvement
after two weeks of therapy
Exclusion criteria
Studies were excluded if the treatment and control groupswere not
well matched, if retreatment patients were included (as this may
affect the organisms sensitivity to the drug under test), if intention
to treat analysis was not used, if there was a large loss to follow up
or if the methodological quality of the study was felt to be poor.
Search methods for identification of studies
See: Cochrane HIV/AIDS Group search strategy
The following databases were searched: MEDLINE, EMBASE,
AIDSLINE, AIDSTRIALS, AIDSDRUGS, CINAHL, LILACS,
Database of Abstracts of Reviews of Effectiveness (DARE), the
Cochrane HIV/AIDS Group register, and the Cochrane Con-
trolled Trials Register (CENTRAL/CCTR) from the date the
database started or from 1980 which ever is later. Abstracts were
reviewed from the relevant conferences. Reference lists of relevant
articles were hand searched. The searches were completed in July
2008. Unpublished data were not included. Journals in languages
other than English were included in the searches if they were in-
dexed in the databases used.
Key words used included: Meningitis, cryptococcus neofor-
mans, treatment, trial, human immunodeficiency virus, acquired
immunodeficiency syndrome, antifungal agents, amphotericin,
flucytosine, fluconazole, azole, lumber puncture, cerebrospinal
fluid pressure and acetazolamide,
Data collection and analysis
Trials identified by the search were assessed for inclusion in the
review. Abstracts of all studies identified were screened by the re-
viewers. Those felt to meet the criteria for inclusion were reviewed
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by the reviewers in full. Where there was a conflict between the
reviewers as to the suitability of a study to be reviewed this was
resolved by discussion or the involvement of a third party (a mem-
ber of the Cochrane HIV AIDS group). Identified studies were
reviewed by the reviewers as to their methodological quality which
was graded as A - adequate, B-unclear, C-inadequate and D-not
done. The assessment of methodological quality was based on
quality of randomisation, allocation concealment, blinding, base-
line characteristics of patients, use of intention to treat analysis
and completeness of follow-up.
Data was extracted from the selected studies by the reviewers using
a standard data extraction form.
Summary ratio measures between trials (odds ratios, relative risks
with 95%confidence intervals), were calculatedwhere appropriate
using Cochrane REVMan software. Heterogeneity between trials
was tested.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Six studies were found that meet the inclusion criteria for the
review and were felt to be of sufficient quality to be included. The
studies are described below divided into groups by the type of
intervention tested. A list of excluded studies with the reason for
exclusion is given in the table “Characteristics of excluded studies.”
Studies looking at methods to treat raised intracranial pres-
sure.
One study Newton 2002 was found that looked at treating raised
ICP. In this study conducted between 1998 and 2000, 22 adult
Thai patients were randomised to receive either acetazolamide
(dose adjusted for weight and serum creatinine) or placebo in ad-
dition to AmB (1mg/kg) for 14 days. Eligible patients had CM
confirmed on Indian Ink staining, headache, GCS>11/15 and
CSF opening pressure >200mm/H2O. Exclusion criteria were;
weight <35kg, renal or electrolyte disturbance, pregnancy or breast
feeding, hypersensitivity to sulphonamides, contraindications for
acetazolamide therapy, systolic blood pressure <100mm Hg, a
known intracerebral lesion or any infection apart from cryptococ-
cosis and HIV. Lumbar puncture and blood tests were performed
on days 2, 4, 7 and 14 after commencement of the acetazolamide/
placebo regime. Primary outcome measures were CSF opening
pressure, headache severity and serum potassium and bicarbonate
levels at 14 days. 21/22 recruited patients were HIV positive. 10
received placebo and 12 received acetazolamide. 2 additional pa-
tients were enrolled in the study but had to be withdrawn as they
were underweight.
Studies comparing different antifungal drugs.
Five other studies were included. Brouwer 2004 compared AmB
to AmB and flucytosine to AmB, flucytosine and fluconazole.
Mayanja-Kizza 1998 compared fluconazole to fluconazole and
flucytosine, van derHorst 1997 comparedAmB toAmBandflucy-
tosine, Bicanic 2008 compared standard dose Amb and flucytosine
to high dose AmB and flucytosine and Leenders 1997 compared
liposomal AmB to standard AmB.
Brouwer 2004 carried out their study in Thailand. Between May
and December 2002, 64 HIV positive adult patients with a
first episode of culture positive cryptococcal meningitis were ran-
domised to receive one of four treatments for 14 days: intra-
venous AmB (0.7mg/kg/day), AmB plus oral flucytosine (100mg/
kg/day), AmB plus oral fluconazole (400mg/day) or triple therapy
with AmB, flucytosine and fluconazole. Unless contraindicated, 1l
0.9% NaCl was administered intravenously to patients before ev-
ery AmB infusion to reduce nephrotoxicity. After 2 weeks, all pa-
tients were treated with oral fluconazole 400mg daily for 8 weeks,
and 200mgdaily thereafter. Exclusion criteria were ALTmore than
five times the upper limit of normal, neutrophil count <500x106/
l, platelet count <50,000x106/l, pregnancy or previous adverse re-
action to study drugs.
Lumbar puncture (LP) was performed on days 3, 7 and 14 of
the study. Additional LPs were done as required on patients with
high CSF pressures. Semi-quantitative cultures were done on CSF
samples at each time point. This allowed the rate of reduction in
the number of colony forming units (CFUs) to be calculated for
each patient. The mean rate of fall in CSF log CFU counts was
used as a marker of early fungicidal activity (EFA) in each study
arm.
16 patients were treated with each of these regimes; AmB
alone, AmB plus fluconazole (AmB+F) and triple therapy
(AmB+5TC+F). Although 16 patients were randomised to receive
AmB plus flucytosine (AmB+5TC) only 15 patients actually par-
ticipated in this study arm as one patient turned out to be HIV
negative. Follow-up of all participants who received study drugs
was done at an established HIV clinic and was complete to 10
weeks.
Mayanja-Kizza 1998 carried out their study in Uganda. Between
January 1994 and May 1994, 58 HIV positive adults were ran-
domised to receive primary therapy with either oral fluconazole
(400mg od on Day 1 then 200mg daily for 2 months) or oral
fluconazole plus flucytosine (150mg/kg/day in 3 split doses for 14
days). All patients who responded to primary therapy were contin-
ued on maintenance therapy with fluconazole at a dose of 200mg
three times per week for 4 more months.
Eligible patients all had positiveCSF cultures forC.neoformans and
either a positive India Ink test or cryptococcal antigen test by latex
agglutination. Pregnant and comatose patients were excluded from
the study. 5 patients were diagnosed with tuberculosis had anti-
tuberculous therapy administered. No adjustment of fluconazole
dose was made during co-prescription of rifampicin.
30 patients received combination therapy, whilst 28 patients re-
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ceived fluconazole alone. Clinical assessments were done weekly
for the first 2months and every twoweeks there after. Patients were
asked to grade their headache as none, mild, moderate or severe at
each review. Repeat lumbar puncture was done at 2 months and 6
months of therapy. Outcomes measured were survival, CSF steril-
isation, clinical success (improvement or resolution of headache)
and occurrence of adverse events.
van der Horst 1997 carried out their study in the United States.
The study had two steps. Step One: Between October 1991 and
August 1994, 381 HIV positive adult patients were randomised
to receive two weeks of AmB 0.7mg/kg daily along with either
flucytosine 100mg/kg/day in four divided doses or placebo. Pa-
tients were eligible if they presented with a first episode of culture-
proven CM and no concurrent opportunistic infections. Patients
were excluded if they had been pre-treated with anti-fungals or
were co-prescribed agents (including rifampicin) which affected
the absorption or metabolism of azole drugs. Comatose patients
were also excluded, as were pregnant women, and those with hae-
matologic, renal and hepatic dysfunction. Outcomes measured at
2 weeks were clinical success (fever, headache and meningism im-
proved or no worse) and mycological success (sterile CSF fungal
culture). 202 patients received AmB and flucytosine, whilst 179
received AmB alone.
Step Two: At two weeks all patients who were clinically stable with
no hepatic dysfunction were randomised to receive oral flucona-
zole (800mg daily for two days, then 400mg daily for eight weeks)
or oral itraconazole (600mg daily for three days, then 300mg daily
for eight weeks). Outcomes measured after this time were clinical
success (absence of fever, headache and meningism) and myco-
logical success (sterile CSF fungal culture). 75 patients dropped
out before this part of the study due to withdrawal of consent (21
patients), death (19 patients), clinical deterioration (11 patients),
inability to take oral medications (1 patient), adverse drug events
(11 patients), co-prescription of prohibited drugs (7 patients) con-
current opportunistic infections (4 patients) and inadequate total
dose of amphotericin B(1 patient). 151 patients received flucona-
zole and 155 received itraconazole. Due to the large drop out rate
this second portion of the study is not included in the analysis
below.
Bicanic 2008 carried out their study in Cape Town, South Africa
between May 2005 and June 2006. Sixty four HIV infected
patients with culture proven c.neoformans meningitis were ran-
domised to receive either AmB 0.7mg/Kg daily (standard dose
AmB) with flucytosine 0.25mg/Kg four times a day for two weeks
or AmB 1mg/Kg daily (high dose AmB) with flucytosine 0.25mg/
Kg four times a day for two weeks. This initial treatment was fol-
lowed by fluconazole 400mg daily for a month then fluconazole
200mg daily afterwards.
Amb infusion was preceded by infusion of 1L of normal saline to
reduce nephrotoxicity, electrolytes were supplemented as neces-
sary. Patients developing renal failure where switched from AmB
to fluconazole. Lumbar punctures were performed on days 3, 7
and 14 of treatment. Additional lumbar punctures were done in
patients with raised ICP or headache.
Eligible patients had to be HIV infected, over 18 years of age,
c.neoformans culture positive in their CSF and have a first episode
of CM. Patients were excluded if they were pregnant or lactating,
if they were taking ARVs, if they had experienced a serious reac-
tion to AmB or flucytosine, had a platelet count under 50 cells/
mm3 , neutrophil count <0.5 cell / mL or an alanine transaminase
level greater than five times normal. Patients with reduced level of
consciousness were included in the study if a relative was available
to give consent. Including these patients meant the investigators
were including very sick patients not normally involved in CM
trials which is highly commendable as these type of patients com-
monly present in clinical practice.
Sixty four patients were randomised, 30 received AmB 0.7mg/Kg
with flucytosine 0.25mg/Kg and 34 received AmB 1 mg/Kg with
flucytosine 0.25mg/Kg. Patients were followed up for one year.
Antiretroviral therapy was commenced after 4 weeks of antifungal
treatment.
The primary outcome measure was the mean rate of decrease of
c.neoformans colony forming units in the CSF, secondary outcome
measures were adverse events related to treatment namely anaemia
and renal failure, mortality at 2 weeks, 10 weeks and long term
survival.
Leenders 1997 conducted their study in theNetherlands and Aus-
tralia between June 1992 and June 1995. 28 HIV infected pa-
tients with culture proven CM were randomised to either 21 days
of AmB 0.7mg/Kg daily or liposomal AmB (AmBisome) 4mg/
Kg daily for 21 days. Both treatments were followed by 7 weeks
of fluconazole 400mg daily then fluconazole 200mg daily indefi-
nitely. Patients were prehydrated with normal saline prior to AmB
infusions. Lumbar punctures were performed on days 7, 14 and
21, also after 10 weeks.
Eligible patients had to be aged over 18, give informed consent,
have a first episode of CM and have culture proven C.neoformans
infection. Exclusion criteria are not clearly stated.
28 patients were randomised, 13 received AmB and 15 liposomal
AmB. Patients were followed up for six months. Combination
ART was not available at the time of this trial.
The outcome measures were mortality, toxicity and adverse events
leading to discontinuation of therapy.
Risk of bias in included studies
The quality of the trials was assessed by the reviewers indepen-
dently. The assessment was based on the quality of allocation con-
cealment, blinding, baseline characteristics of patients, use of in-
tention to treat analysis and completeness of follow-up. They are
graded A - adequate, B - unclear, C - inadequate, D - not done.
Quality of allocation concealment:
The study by Bicanic 2008, Brouwer 2004, Leenders 1997 and
Mayanja-Kizza 1998 used sealed envelopes for treatment alloca-
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tion and were graded A. In the other three studies Newton 2002
and van derHorst 1997 allocation concealment was unclear there-
fore these studies were graded B.
Blinding:
The study by Newton 2002 was double blind and graded A. The
study by van derHorst 1997 had two phases the first phase was un-
blinded and the second phase was double blind therefore the study
was graded D/A. The other three studies Bicanic 2008, Brouwer
2004, Leenders 1997 and Mayanja-Kizza 1998 were unblinded
and graded D.
Baseline characteristics of patients:
In all Six studies attempts were made to carefully match patients
in all groups for baseline characteristics. All studies were graded
A.
Use of intention to treat analysis:
All Six trials used intention to treat analysis and were graded A.
Completeness of follow-up:
Loss to followupof less then5%of the total number of patients en-
rolled was reported in Brouwer 2004 and Leenders 1997. Bicanic
2008 reported 1/64 patients lost to follow up at 10 weeks and 3/64
at 1 year. These three studies were graded A. Mayanja-Kizza 1998
reported 8/58 patients lost to follow up, Newton 2002 reported
12/24, these trials were graded C. van der Horst 1997 reported
21/306 patients were lost to follow up in stage 2 of their study,
this trial was graded C.
Effects of interventions
Acetazolamide vs placebo
Only one study addressed treating raised intracranial pressure,
Newton 2002. This study used acetazolamide. No studies of re-
peated lumbar puncture were found. The study by Newton 2002
was terminated early by the safety monitoring committee due to
the observationof excess deaths 2/12 vs 0/10 relative risk (RR) 4.23
95% confidence interval (95% CI) 0.23 to 79.1 and excess serious
adverse events 5/12 vs 0/10 RR 9.31 95% CI 0.58 to 150.25 in
the group of patients receiving acetazolamide. Although these ex-
cess events did not reach statistical significance in this small study,
acetazolamide can not be recommended for the management of
increased intracranial pressure.
Fluconazole and flucytosine vs fluconazole
Mayanja-Kizza 1998 compared fluconazole to fluconazole and
flucytosine. The dose of fluconazole used 200mg daily is lower
than the currently recommended dose of 400mg daily. Flucytosine
was given at a dose of 150mg/kg daily. There was no difference
in death rate at two weeks 4/25 Vs 10/25 RR 0.4 95% CI 0.14
to 1.11 or at six months 17/25 Vs 22/25 RR0.77 95%CI 0.57 to
1.05. Also there was no difference in number of patients with ster-
ile CSF at 2 months after treatment 4/8 Vs 12/15 RR 0.4 95%CI
0.11 - 1.36. There were no major adverse events in either group.
AmB vs AmB and flucytosine
Brouwer 2004 and van der Horst 1997 compared AmB 0.7mg/
kg daily to AmB 0.7mg/kg daily with flucytosine 100mg/kg per
day. The studies were analysed together for the outcomes of death
at 14 days and sterility of CSF culture at 14 days. There was no
difference in the proportion deaths at 14 days 12/195 Vs 12/217
RR1.1 95%CI 0.51 to 2.4, but there was higher proportion of
patientswith sterileCSF cultures at 14days in the groupof patients
receiving flucytosine 93/195 Vs 128/217 RR0.81 95%CI 0.68 to
0.98. There was no difference in major adverse events between
the two treatment arms 5/195 Vs 6/217 RR 0.94 95% CI 0.29 to
3.03.
Brouwer 2004 recorded deaths at 10 weeks there was no difference
between the two groups 3/16 Vs 1/16 RR 2.81 95%CI 0.33 to
24.16.
van der Horst 1997 found no difference in symptomatic improve-
ment at 14 days between the two groups 149/179 Vs 157/202 RR
1.07 95%CI 0.97 to 1.18.
AmB vs AmB, flucytosine and fluconazole
Brouwer 2004 compared AmB to AmB, flucytosine and flucona-
zole. AmB was given at a dose of 0.7mg/kg daily, flucytosine
100mg/kg daily and fluconazole was given at a dose of 400mg
daily. There was no significant difference in the proportion of pa-
tients dying at twoweeks or tenweeks 2/16Vs 1/16RR2.0 95%CI
0.2 to 19.91 and 3/16 Vs 3/16 RR 1.0 95%CI 0.24 to 4.23. There
was also no difference in the proportion of patients sterile CSF at
14 days 2/16 Vs 4/16 RR0.5 95%CI 0.11 to 2.35. There were no
serious adverse events in either group.
AmB and flucytosine vs AmB, flucytosine and fluconazole
Brouwer 2004 compared AmB and flucytosine to AmB, flucyto-
sine and fluconazole. There was no difference in death at 14 days
or 10 weeks between the groups 1/15 Vs 1/16 RR 1.07 95%CI
0.07 to 15.57 and 1/15 Vs 3/16 RR 1.07 95%CI 0.07 to 15.57.
Also there was no difference in the proportion of patients with
sterile CSF at 14 days 6/15 Vs 4/16 RR 1.6 95%CI 0.56 to 4.58.
There were no serious adverse events in either group.
AmB and flucytosine vs AmB and fluconazole
Brouwer 2004 compared AmB and flucytosine to AmB and flu-
conazole. There was no difference in the proportion of deaths at
14 days or 10 weeks 1/15 Vs 5/16 RR 0.21 95%CI 0.03 to 1.62
and 1/15 Vs 7/16 RR 0.15 95%CI 0.02 to 1.1. Also there was no
difference in the amount of patients with sterile CSF at 14 days 6/
15 Vs 3/16 RR 2.13 95%CI 0.65 to 7.04. There were no serious
adverse events in either group.
AmB vs AmB and fluconazole
Brouwer 2004 compared AmB to AmB and fluconazole. There
was no difference in the proportion deaths at 14 days or 10 weeks
2/16 Vs 5/16 RR 0.4 95%CI 0.09 to 1.77 and 3/16 Vs 7/16 RR
0.43 95% CI 0.13 to 1.37. Also there was no difference in the
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amount of patients with sterile CSF at 14 days 2/16 Vs 3/16 RR
0.67 95%CI 0.13 to 3.47. There were no serious adverse events
in either group.
AmB and fluconazole vs AmB, flucytosine and fluconazole
Brouwer 2004 compared AmB and fluconazole to AmB, flucyto-
sine and fluconazole. There was no difference in the proportion
deaths at 14 days or 10 weeks 5/16 Vs 1/16 RR 5.0 95%CI 0.66
to 38.15 and 7/16 Vs 3/16 RR 2.33 95%CI 0.73 to 7.45. Also
there was no difference in the amount of patients with sterile CSF
at 14 days 3/16 Vs 4/16 RR 0.75 95%CI 0.2 to 2.83. There were
no serious adverse events in either group.
Standard dose AmB and Flucytosine Vs high dose AmB and
flucytosine.
Bicanic 2008 compared AmB0.7mg/Kgwith flucytosine 0.25mg/
Kg for 2 weeks with AmB 1 mg/Kg with flucytosine 0.25mg/Kg
for 2 weeks. There was no difference in the proportion of deaths
at 14 days or 10 weeks 1/30 Vs 3/34 RR0.34 95% CI 0.04 - 3.44
and 6/30 Vs 9/34 RR 0.76 95% CI 0.03 - 1.83. The proportion
of patients with sterile CSF at 14 days was not different between
the two treatment groups 6/29 Vs 7/28 RR 1.13 95% CI 0.43 -
2.94. There was also no major difference in major adverse events
defined as side effects of treatment leading the study interventions
being terminated 1/30 Vs 5/34 RR 0.23 95% CI 0.03 - 1.83.
AmB Vs liposomal AmB
Leenders 1997 compared AmB 0.7mg/Kg daily for 21 days with
liposomal AmB4mg/Kg daily for 21 days. There was no difference
in the proportion of patients who had a clinical response after 3
weeks treatment 12/15 in the liposomal AmB group Vs 11/13
in the AmB group RR 0.95 95% CI 0.67 - 1.33. There was no
difference in the proportion of deaths at 14 days, 10 weeks or 6
months. At 6 months 2/15 patients who received liposomal AmB
had died and 1/13 patients who received AmB RR 1.73 95%CI
0.12 - 59.4.
Major adverse events were less common in patients who received
liposomal AmB 2/15 Vs 9/13 RR 0.19 95% CI 0.05 - 0.74.
There was no statistically significant difference in the proportion
of patients with sterile CSF at 14 days in either group but the trend
suggests that liposomal AmB was superior with 10/15 patients
having sterile CSF Vs 1/9 in the AmB group RR 6.0 95% CI 0.91
- 39.41.
In Summary.
Newton 2002 compared acetazolamide to placebo for reducing
raised ICP. This study was terminated due to safety concerns and
therefore acetazolamide cannot be recommended formanagement
of raised ICP in CM.
Mayanja-Kizza 1998 compared fluconazole to fluconazole with
5 flucytosine. The dose of fluconazole used 200mg initially is
lower than the recommended initial dose of 400mg. No survival
advantage was found with the use of 5 flucytosine in addition to
fluconazole.
Two studies Brouwer 2004 and van der Horst 1997 compared
AmB to AmB with 5 flucytosine. Both drugs were given at cur-
rently recommended doses for 2 weeks. No survival difference was
found at 14 days or at 10 weeks (only recorded in Brouwer 2004).
There were significantly more patients with sterile CSF cultures
at 14 days in the group that received AmB with flucytosine.
Brouwer 2004 compared AmB given alone to AmB given with
flucytosine and fluconazole alone or in combination. This was a
small study and no differences in mortality were noted between
the groups.
Bicanic 2008 compared high to standard dose AmB both with
flucytosine. There was no difference in mortality between the two
groups or adverse events.
Leenders 1997 compared standard to liposomal AmB. There was
no difference in death rates between the two groups. But there were
significantly fewer side effects in the group treated with liposomal
AmB.
D I S C U S S I O N
Six studies were found that met the inclusion criteria. Five of the
studies compared antifungal treatments and one study Newton
2002 addressed lowering intracranial pressure, this study was ter-
minated prematurely by the safety monitoring committee due to
concerns over excess mortality in the intervention group who re-
ceived acetazolamide. Therefore acetazolamide can not be recom-
mended for the management of raised ICP in CM. No studies
were found that examined the use of repeated lumbar puncture in
the management of raised ICP. A limitation of the studies of an-
tifungal therapy reviewed is that different approaches to control-
ling raised intracranial pressure were used. It is felt that aggressive
management of raised ICP has an important impact on mortality
and long term neurological disability Pappas 2005; Saag 2000.
This difference in management may have impacted on survival
differences between the studies, for example van der Horst 1997
used a combination of repeat lumbar punctures and acetazolamide
to lower raised ICP, acetazolamide has subsequently been associ-
ated with adverse outcomes Newton 2002. The method of opti-
mal management of raised ICP remains an important unanswered
question that could significantly impact on survival.
The main aim of this review was to determine the best treatment
for cryptococcal meningitis with an emphasis on resource-limited
settings. In these settings usually only AmB and fluconazole are
available. No study suitable for inclusion was found that directly
compared AmB to Fluconazole for primary treatment of CM.
Therefore we are unable comment or to recommend either treat-
ment as superior to the other.
The addition of flucytosine to AmB increased the proportion of
patients with sterile CSF cultures at 14 days but this did not trans-
late into a survival benefit during the follow up period of the stud-
ies reviewed. It is not known if over a longer period faster sterili-
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sation of CSF will confer a survival advantage but it may well do
so, therefore it is recommended where possible to treat patients
with a combination of AmB and flucytosine. High dose AmB did
not impact on early mortality even though there was a trend to
wards better fungicidal activity. There is insufficient evidence to
recommend to recommend high dose AmB over standard dose
AmB when combined with flucytosine.
Liposomal AmBwas found to be associatedwith less adverse events
compared to standard AmB but the overall outcome as the same.
Liposomal AmB in view if its high cost is not available in public
facilities in resource-limited settings. But this formulation does
have a role where resources are not an issue and especially in pa-
tients with co morbidities such as renal impairment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No evidence was found to recommend the use of fluconazole in
place of AmB as first line therapy for CM. No evidence was found
to recommend the frequency of lumbar punctures necessary to
control raised ICP. In view of the superior antifungal activity of
AmB / flucytosine combination therapy, policy makers in national
departments of health should consider making flucytosine avail-
able to public HIV treatment programmes in all settings.
Implications for research
Future research into the management of cryptococcal meningitis
in resource-limited settings should focus on the most effective use
of medications that are available in these settings. For example the
combination of AmB and fluconazole could be compared to AmB
alone. Also studies looking at the best time to initiate ART in re-
lation to an acute episode of CM are needed. Optimal dosing of
both fluconazole and amphoteracin also needed to be elucidated,
namely doses that improve survival without causing excessive tox-
icity.
Also ideal management of raised intracranial pressure needs to be
determined. A trial looking at various regimens for repeat lumbar
puncture to control raised ICP is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bicanic 2008
Methods Randomised trial
Participants HIV infected adults with cryptococcal meningitis in South Africa
Interventions Amphoteracin 0.7mg/Kg and flucytosine Vs Amphoteracin 1mg/Kg and flucytosine
Outcomes Death
Mycological outcome
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Brouwer 2004
Methods Randomised trial
Participants HIV infected adults with cryptococcal meningitis in Thailand
Interventions Amphoteracin B Vs amphoteracin B and flucytosine Vs amphoteracin B and fluconazole
Vs amphoteracin B, flucytosine and fluconazole
Outcomes Death, mycological outcome
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
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Leenders 1997
Methods Randomised trial
Participants HIV infected adults with cryptococcal meningitis in Holland and Australia
Interventions Ambisome Vs amphoteracin
Outcomes Death
Mycological outcome
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Mayanja-Kizza 1998
Methods Randomised trial
Participants HIV infected adults with cryptococcal meningitis in Uganda
Interventions Fluconazole and flucytosine Vs fluconazole
Outcomes Death, headache severity, mycological response
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Newton 2002
Methods Randomised double blind trial
Participants HIV infected adults with cryptococcal meningitis in Thailand
Interventions Acetzolamide Vs placebo
Outcomes CSF opening pressure, headache severity, serum potassium and bicarbonate levels
Notes
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Newton 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk D - Not used
van der Horst 1997
Methods Randomised double blind trial
Participants HIV infected adults with cryptococcal meningitis in the USA
Interventions Step one - amphoteracin B and flucytosine Vs. amphoteracin B. Step 2. Maintainence
therapy with fluconazole Vs maintainence therapy with itraconazole
Outcomes Death, resolution of headache, meningism and fever. Mycological response at 2 weeks and
10 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk D - Not used
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brouwer 2007 This is a substudy of Brouwer 2004.
Chotmongkol 1997 This study included retreatment patients, which may have biased the results
Chotmongkol 2005 Control and study group not well matched for severity of disease
de Gans 1992 Several patients were lost to follow up and several patients were switched from the itraconazole to am-
photeracin treatment arm due to deterioration in thier clinical condition. In such a small study this factors
may have affected the conclusions reached about treatment efficacy
Larsen 1990 This was a small study where many patients were excluded before randomisation. Also intention to treat
analysis was not used meaning 6/26 patients were excluded from the final analysis. Also the two groups
were not well matched for CD4 counts
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(Continued)
Saag 1992 This study included 8 patients who were retreatment patients. This may bias the results as the patients
may have C.neformans infection that is resistant to the treatments under trail due to previous exposure
Sharkey 1996 Control and study groups are poorly matched for baseline characteristics
Tansuphaswadikul2006 Large loss to follow at end of 10 week period. Fifteen patients (50%) lost in group of individuals given 1
week treatment with amphoteracin
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D A T A A N D A N A L Y S E S
Comparison 1. Acetzolamide Vs placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 22 Risk Ratio (M-H, Fixed, 95% CI) 4.23 [0.23, 79.10]
2 Serious adverse event 1 22 Risk Ratio (M-H, Fixed, 95% CI) 9.31 [0.58, 150.25]
Comparison 2. Fluconzaole and flucytosine Vs fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 2 weeks 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.14, 1.11]
2 Death at six months 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.57, 1.05]
3 Major adverse events 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culture at 2 months 1 23 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.12, 1.36]
Comparison 3. Amphoteracin Vs fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Death after 10 weeks 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Major adverse events 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Amphoteracin Vs amphoteracin and flucytosine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 2 412 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.60, 2.85]
2 Death at 10 weeks 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.81 [0.33, 24.16]
3 Major adverse events 2 412 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.29, 3.03]
4 Sterile CSF culture at 14 days 2 412 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.68, 0.98]
5 Symptomatic improvement at
14 days
1 381 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.97, 1.18]
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Comparison 5. Amphoteracin Vs amphoteracin, flycytosine and fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 19.91]
2 Death at 10 weeks 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.24, 4.23]
3 Major adverse event 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culture at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.11, 2.35]
Comparison 6. Amphoteracin and flucytosine Vs amphoteracin, flucytosine and fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
2 Death at 10 weeks 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.07, 15.57]
3 Major adverse event 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culture at 14 days 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.6 [0.56, 4.58]
Comparison 7. Amphoteracin and flucytosine Vs amphoteracin and fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.03, 1.62]
2 Death at 10 weeks 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.10]
3 Major adverse events 1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culture at 14 days 1 31 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.65, 7.04]
Comparison 8. Amphoteracin Vs amphoteracin and fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.09, 1.77]
2 Death at 10 weeks 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.13, 1.37]
3 Major adverse events 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culture at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.13, 3.47]
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Comparison 9. Amphoteracin and fluconazole Vs amphoteracin, flucytosine and fluconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.66, 38.15]
2 Death at 10 weeks 1 32 Risk Ratio (M-H, Fixed, 95% CI) 2.33 [0.73, 7.45]
3 Major adverse event 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Sterile CSF culuture at 14 days 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.20, 2.83]
Comparison 10. Standard dose amphoteracin and flucytosine Vs high dose amphoteracin and flucytosine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.04, 3.44]
2 Death at 10 weeks 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.30, 1.87]
3 Major adverse event 1 64 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.03, 1.83]
4 Sterile CSF at 14 days 1 57 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.43, 2.94]
Comparison 11. Amphoteracin Vs liposomal amphoteracin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 14 days 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Death at 10 weeks 1 28 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.12, 59.40]
3 Death at 6 months 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.18, 16.99]
4 Major adverse events 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.05, 0.74]
5 Sterile CSF culture at 14 days 1 24 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.91, 39.41]
6 Proportion of patients
responding clinically after 3
weeks treatment
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.67, 1.33]
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